Home > Boards > US Listed > Medical - Drugs > Athenex (ATNX)

Companies are exploring the clinical benefits of fusing

Public Reply | Private Reply | Keep | Last ReadPost New MsgNext 10 | Previous | Next
Leotrader211 Member Profile
 
Followed By 3
Posts 504
Boards Moderated 0
Alias Born 09/18/17
160x600 placeholder
Small Company Offering and Sale of Securities Without Registration (d) Edgar (US Regulatory) - 5/15/2019 6:16:48 AM
Quarterly Report (10-q) Edgar (US Regulatory) - 5/9/2019 8:40:40 AM
Current Report Filing (8-k) Edgar (US Regulatory) - 5/9/2019 7:06:45 AM
Athenex, Inc. Announces First Quarter 2019 Financial Results and Provides Corporate Update GlobeNewswire Inc. - 5/9/2019 7:00:00 AM
Statement of Changes in Beneficial Ownership (4) Edgar (US Regulatory) - 5/8/2019 5:06:58 PM
Initial Statement of Beneficial Ownership (3) Edgar (US Regulatory) - 5/8/2019 4:55:40 PM
Amended Statement of Ownership (sc 13g/a) Edgar (US Regulatory) - 5/8/2019 4:02:17 PM
Current Report Filing (8-k) Edgar (US Regulatory) - 5/6/2019 8:06:56 AM
Athenex Announces $100 Million Private Placement GlobeNewswire Inc. - 5/6/2019 8:00:00 AM
Athenex Announces Promising Early and Complete Response Data from a Clinical Study of Oraxol in Cutaneous Angiosarcoma GlobeNewswire Inc. - 5/3/2019 9:12:18 AM
Statement of Changes in Beneficial Ownership (4) Edgar (US Regulatory) - 4/25/2019 4:11:44 PM
Additional Proxy Soliciting Materials (definitive) (defa14a) Edgar (US Regulatory) - 4/25/2019 7:03:49 AM
Proxy Statement (definitive) (def 14a) Edgar (US Regulatory) - 4/25/2019 7:02:03 AM
Athenex, Inc. to Report First Quarter 2019 Earnings Results on May 9, 2019 GlobeNewswire Inc. - 4/25/2019 7:00:00 AM
Athenex Announces Abstracts Accepted for Presentation at the 2019 American Society of Clinical Oncology Annual Meeting GlobeNewswire Inc. - 4/23/2019 7:00:00 AM
Statement of Changes in Beneficial Ownership (4) Edgar (US Regulatory) - 4/17/2019 4:26:43 PM
Statement of Changes in Beneficial Ownership (4) Edgar (US Regulatory) - 4/17/2019 4:23:54 PM
Statement of Changes in Beneficial Ownership (4) Edgar (US Regulatory) - 4/17/2019 4:20:38 PM
Statement of Changes in Beneficial Ownership (4) Edgar (US Regulatory) - 4/17/2019 4:15:06 PM
Statement of Changes in Beneficial Ownership (4) Edgar (US Regulatory) - 4/17/2019 4:11:47 PM
Statement of Changes in Beneficial Ownership (4) Edgar (US Regulatory) - 4/9/2019 4:28:35 PM
Statement of Changes in Beneficial Ownership (4) Edgar (US Regulatory) - 4/9/2019 4:25:09 PM
Statement of Changes in Beneficial Ownership (4) Edgar (US Regulatory) - 4/9/2019 4:21:48 PM
Statement of Changes in Beneficial Ownership (4) Edgar (US Regulatory) - 4/9/2019 4:11:49 PM
Statement of Changes in Beneficial Ownership (4) Edgar (US Regulatory) - 4/2/2019 4:30:06 PM
Leotrader211   Monday, 02/05/18 01:23:00 PM
Re: None
Post # of 14 
Companies are exploring the clinical benefits of fusing new chemical entities in existing drugs on treatment of bile duct cancer. The key players in global bile duct cancer treatment market are also seeking regulatory approval of combination therapies for treatment of Cholangiocarcinoma. The study has recorded such developments while profiling the market’s leading participants, which include Pfizer, Inc., F. Hoffman-La Roche AG, Bristol-Myers Squibb Company, Teva Pharmaceuticals Industries Ltd., Eli Lilly and Company, Novartis AG, Sanofi, Fresenius Kabi AG, Mylan N.V., Kyowa Hakko Kirin Co Ltd., Intercept Pharmaceuticals, Inc., Accord Healthcare Inc., Delcath Systems Inc.,Celgene Corporation, and Johnson & Johnson. 

http://www.satprnews.com/2018/02/05/global-bile-duct-cancer-treatment-market-will-reach-a-valuation-of-us-144-2-mn-between-2017-and-2025/ ;


Public Reply | Private Reply | Keep | Last ReadPost New MsgNext 10 | Previous | Next
Follow Board Follow Board Keyboard Shortcuts Report TOS Violation
X
Current Price
Change
Volume
Detailed Quote - Discussion Board
Intraday Chart
+/- to Watchlist